Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Beijing Biotech
Orano Med LLC
Filamon LTD
Essen Biotech
Essen Biotech
Sapience Therapeutics
Var2 Pharmaceuticals
Mayo Clinic
Merck Sharp & Dohme LLC
Incyte Corporation
Taiho Oncology, Inc.
Novartis
LigaChem Biosciences, Inc.
Institut du Cancer de Montpellier - Val d'Aurelle
SK Life Science, Inc.
Stanford University
Cedars-Sinai Medical Center
University Hospital, Antwerp
NGM Biopharmaceuticals, Inc
Prelude Therapeutics
Cedars-Sinai Medical Center
Stanford University
Nuvation Bio Inc.
Quadriga Biosciences, Inc.
Gan and Lee Pharmaceuticals, USA
Gilead Sciences
Hospices Civils de Lyon
Novartis
DEKK-TEC, Inc.
Celgene
Cambridge University Hospitals NHS Foundation Trust
Tocagen Inc.
Stanford University
AbbVie
Roswell Park Cancer Institute
M.D. Anderson Cancer Center
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Novartis
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)
Case Comprehensive Cancer Center
Pharmacyclics LLC.
Siemens Molecular Imaging